Could fasting boost breast cancer drugs? new study investigates

NCT ID NCT07624617

Recruiting now Knowledge-focused Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 4 times

Summary

This study looks at whether a special fasting schedule (eating only dinner) can make PI3K inhibitor drugs work better against metastatic breast cancer. Researchers will check if patients can stick with the fasting plan and study blood samples to see how fasting affects cancer cells in the lab. Only 15 people will take part, and the goal is to gather early clues, not to prove a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: prolonged fasting (behavioral intervention)
What this could lead to: If successful, this could point toward a way to make existing cancer drugs work better by adding a fasting regimen.
What could go wrong: This is a very small, early-stage trial (15 people) that only measures biological markers, not patient outcomes. Fasting may be hard to tolerate and may not improve treatment effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.